(Q33748023)

29 July 2017

1 reference

title

Zanamivir: a review of clinical safety (English)

1 reference

29 July 2017

1 reference

2

S Gravenstein

1 reference

29 July 2017

B Freund

1

1 reference

29 July 2017

M Elliott

series ordinal

3

1 reference

29 July 2017

I Miller

series ordinal

4

1 reference

29 July 2017

1 October 1999

1 reference

29 July 2017

1 reference

29 July 2017

21

1 reference

29 July 2017

4

1 reference

29 July 2017

267-281

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-199921040-00003

29 July 2017

0 references

cites work

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections

1 reference

12 December 2020

Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group

1 reference

12 December 2020

Clinical features of influenza.

1 reference

12 December 2020

Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks.

1 reference

12 December 2020

Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers

1 reference

12 December 2020

Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase)

1 reference

12 December 2020

Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group.

1 reference

12 December 2020

The low potential for drug interactions with zanamivir

1 reference

12 December 2020

Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial

1 reference

12 December 2020

A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection

1 reference

12 December 2020

Rational design of potent sialidase-based inhibitors of influenza virus replication

1 reference

12 December 2020

Successful treatment of naturally occurring influenza A/USSR/77 H1N1.

1 reference

12 December 2020

Preclinical development of low toxicity drugs: focus on zanamivir, an anti-influenza drug

1 reference

12 December 2020

Influenza: quantifying morbidity and mortality

1 reference

12 December 2020

Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers

1 reference

12 December 2020

4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro

1 reference

12 December 2020

Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza

1 reference

12 December 2020

10.2165/00002018-199921040-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference